Department of Hematology/Oncology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea
Copyright © 2021 Yeungnam University College of Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ethical statements
This study was approved by the Institutional Review Board (IRB) of Kyungpook National University Chilgok Hospital (IRB No: KNUCH 2021-02-007). The patient provided written informed consent for publication of clinical details.
Conflicts of interest
No potential conflict of interest relevant to this article was reported.
Author contributions
Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Visualization, Investigation, Validation: all authors; Resources, Supervision: YSC, Writing-original draft, Writing-review & editing: all authors.
Variable | Ipilimumab | Nivolumab | Pembrolizumab | Atezolizumab |
---|---|---|---|---|
Case of AIHA/OAEa) | 7/12,631 (0.055) | 43/20,335 (0.211) | 13/8,917 (0.146) | 5/2,021 (0.247) |
Age (yr)b) | 65 (32–68) | 68 (43–85) | 62 (35–82) | 67 (57–69) |
Underlying malignancy | MM: 7 | LC: 18, MM: 17c), HL: 3c), RCC: 2, Others: 4 | MM: 7, LC: 5, Others: 1 | BC: 2, LC: 1, MM: 1, OC: 1 |
Other reported hematological adverse event with AIHA | Agranulocytosis, bicytopenia | ITP | ITP, PRCA | - |
AIHA, autoimmune hemolytic anemia; OAE, overall adverse events; FDA, U.S. Food and Drug Administration; MM, malignant melanoma; LC, lung cancer; HL, Hodgkin lymphoma; RCC, renal cell carcinoma; BC, breast cancer; OC, ovarian cancer; ITP, immune thrombocytopenic purpura; PRCA, pure red cell aplasia.
a)Number (%).
b)Median (range).
c)One patient had both HL and MM.
Investigation | Result (normal range) |
---|---|
Hemoglobin (g/dL) | 5.8 (11–17) |
Reticulocytes (×109/L) | 160 (22–139) |
Total bilirubin (mg/dL) | 4.16 (0.3–1.2) |
Lactate dehydrogenase (U/L) | 478 (140–271) |
Haptoglobin (mg/dL) | <10 (30–200) |
Direct antiglobulin test | Positive |
Cold agglutinin | Positive |
Variable | Ipilimumab | Nivolumab | Pembrolizumab | Atezolizumab |
---|---|---|---|---|
Case of AIHA/OAE |
7/12,631 (0.055) | 43/20,335 (0.211) | 13/8,917 (0.146) | 5/2,021 (0.247) |
Age (yr) |
65 (32–68) | 68 (43–85) | 62 (35–82) | 67 (57–69) |
Underlying malignancy | MM: 7 | LC: 18, MM: 17 |
MM: 7, LC: 5, Others: 1 | BC: 2, LC: 1, MM: 1, OC: 1 |
Other reported hematological adverse event with AIHA | Agranulocytosis, bicytopenia | ITP | ITP, PRCA | - |
AIHA, autoimmune hemolytic anemia; OAE, overall adverse events; FDA, U.S. Food and Drug Administration; MM, malignant melanoma; LC, lung cancer; HL, Hodgkin lymphoma; RCC, renal cell carcinoma; BC, breast cancer; OC, ovarian cancer; ITP, immune thrombocytopenic purpura; PRCA, pure red cell aplasia. Number (%). Median (range). One patient had both HL and MM.